Five ESMO 2026 abstracts report responses with 4 antibody-drug conjugates in ovarian cancer and a subcutaneous HER2-directed ADC plus PD-L1 inhibitor in cervical cancer.
|Videos|February 28, 2018
Developing Combination Therapy Strategies for Ovarian Cancer
Author(s)Kathleen Moore, MD
Kathleen Moore, MD, associate director for clinical research at the Stephenson Oklahoma Cancer Center, discusses the development of combination therapy strategies for patients with ovarian cancer.
Advertisement
Kathleen Moore, MD, associate director for clinical research at the Stephenson Oklahoma Cancer Center, discusses the development of combination therapy strategies for patients with ovarian cancer.
Immunotherapy combinations are currently being tested in many clinical trials for patients with ovarian cancer. Moore says immune agents are being combined with antiangiogenic agents, PARP inhibitors, cytotoxic chemotherapy, as well as other immune agents.
Advertisement
Related to this article
New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
ESMO 2026 Presidential Symposium III: ADC and immunotherapy highlights from the the ARTEMIS-011, TroFuse-005, KEYNOTE-C93, and MOIO trials.
The antibody-drug conjugate sofetabart mipitecan showed efficacy and safety, leading to selection of a phase 3 dose for the FRAmework-01 trial.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5